In community SCLC care, molecular strategies are not monolithic. Genomic alteration testing (NGS) is ready for immediate use and can identify targets today. In contrast, neuroendocrine subtyping is still investigational and not yet clinically actionable, pending results from research studies.

Patients with EGFR-mutant NSCLC that transforms into small cell lung cancer show poor responses to new therapies like tarlatamab, which are highly effective in de novo small cell cancer. This highlights a distinct biology that requires different therapeutic strategies and dedicated clinical trials.

An individual tumor can have hundreds of unique mutations, making it impossible to predict treatment response from a single genetic marker. This molecular chaos necessitates functional tests that measure a drug's actual effect on the patient's cells to determine the best therapy.

Standard DNA-based Next-Generation Sequencing (NGS) can miss critical gene fusions, like ROS1. RNA sequencing is much more effective at identifying these specific alterations, so clinicians should ensure their chosen assay includes RNA analysis to avoid missing opportunities for targeted therapy.

The ongoing SWOG PRISM study represents a paradigm shift for small cell lung cancer (SCLC). By analyzing gene expression profiles to identify molecular subtypes during initial therapy, the trial aims to assign patients to different targeted agents. This moves away from the current one-size-fits-all strategy towards a personalized approach based on underlying tumor biology.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

Unlike breast or lung cancer where a biomarker's effectiveness persists across treatment stages, biomarkers in upper GI cancers often fail to show similar efficacy when moved from one line of therapy to another. This suggests a more variable and rapidly changing tumor biology.

Contrary to its traditional monolithic treatment approach, SCLC is now understood to have distinct transcriptomic subsets (e.g., ASCL1, NeuroD1). The future of SCLC therapy will likely involve biomarker testing to match patients with the most effective treatments for their specific subtype, mirroring the personalized approach in non-small cell lung cancer.

Emerging data suggests SCLC molecular subtypes (e.g., ASCL1, POU2F3) correlate with tarlatumab response. However, this research is too premature to guide clinical decision-making. Clinicians are strongly cautioned against altering patient management based on this "intriguing but not yet proven" subtype data.